antiviral and associated therapy for COVID-19: living meta-analysis of clinical studies

Table Graph

antiviral and associated therapy - versus antiviral and associated therapy - for COVID 19 hospitalized pdf xlsx method abbreviations

Outcome	Relative effect 95%CI	Trt. better when	I2	k (RCT/OBS)	Bayesian probability	Overall ROB	Publication bias	Degree of certainty	Endpoint importance	Published MA
efficacy endpoints 00
deaths	1.01 [0.71, 1.43]	< 1	0%	8 studies (8/-)	48.5 %	some concern	not evaluable	moderate	crucial	-
deaths (time to event analysis only)	0.94 [0.51, 1.73]	< 1	0%	1 study (1/-)	57.9 %	NA	not evaluable		crucial	-
clinical deterioration	1.07 [0.63, 1.82]	< 1	0%	1 study (1/-)	40.2 %	NA	not evaluable		important	-
clinical improvement	1.49 [0.64, 3.48]	> 1	86%	3 studies (3/-)	82.3 %	some concern	not evaluable	moderate	important	-
clinical improvement (14-day)	1.48 [1.05, 2.08]	> 1	0%	2 studies (2/-)	98.8 %	some concern	not evaluable	moderate	important	-
clinical improvement (7-day)	1.46 [0.95, 2.23]	> 1	0%	1 study (1/-)	95.8 %	NA	not evaluable		important	-
clinical improvement (time to event analysis only)	1.15 [0.70, 1.87]	> 1	84%	3 studies (3/-)	70.9 %	some concern	not evaluable	moderate	important	-
hospital discharge	1.34 [0.62, 2.90]	> 1	76%	2 studies (2/-)	77.3 %	some concern	not evaluable	moderate	important	-
mechanical ventilation	0.53 [0.05, 5.86]	< 1	87%	2 studies (2/-)	69.5 %	some concern	not evaluable	moderate	important	-
radiologic improvement (14-day)	1.33 [0.94, 1.88]	> 1	0%	1 study (1/-)	94.7 %	NA	not evaluable		important	-
radiologic improvement (7-day)	0.42 [0.01, 17.35]	> 1	74%	2 studies (2/-)	32.5 %	some concern	not evaluable	moderate	important	-
viral clearance	1.19 [0.28, 5.11]	> 1	84%	3 studies (3/-)	59.4 %	some concern	not evaluable	moderate	important	-
viral clearance (time to event analysis only)	4.37 [1.86, 10.25]	> 1	0%	1 study (1/-)	100.0 %	NA	not evaluable		important	-
viral clearance by day 14	1.10 [0.95, 1.26]	> 1	0%	2 studies (2/-)	89.5 %	some concern	not evaluable	moderate	important	-
viral clearance by day 7	0.82 [0.28, 2.35]	> 1	58%	3 studies (3/-)	35.3 %	some concern	not evaluable	moderate	important	-
ICU admission	1.30 [0.83, 2.04]	< 1	0%	2 studies (2/-)	12.9 %	some concern	not evaluable	moderate	non important	-
recovery	0.81 [0.64, 1.03]	> 1	0%	1 study (1/-)	4.4 %	NA	not evaluable		non important	-
severe COVID-19 occurrence	0.30 [0.07, 1.27]	< 1	0%	1 study (1/-)	94.9 %	NA	not evaluable		non important	-
safety endpoints 00
serious adverse events	0.43 [0.03, 5.81]	< 1	0%	2 studies (2/-)	73.6 %	some concern	not evaluable	moderate	important	-
adverse events	3.29 [0.45, 23.99]	< 1	0%	2 studies (2/-)	12.2 %	some concern	not evaluable	moderate	non important	-
serious adverse events (SAE), any	0.50 [0.32, 0.79]	< 1	0%	1 study (1/-)	99.9 %	NA	not evaluable		non important	-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.

antiviral and associated therapy - versus antiviral and associated therapy - for COVID 19 hospitalized pdf xlsx method abbreviations

efficacy endpoints 00

safety endpoints 00